Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-10-12
1996-04-02
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530384, 530350, 530395, 514 12, 514 21, A61K 3514, A61K 3848, A61K 3816, C07K 14745
Patent
active
055040675
ABSTRACT:
It has been discovered that it is possible to administer truncated tissue factor, not having the transmembrane region (tTF) in combination with factor VIIa (FVIIa) to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. Preferably, the tTF is administered to produce up to 10 .mu.g tTF/ml of plasma. The FVIIa is administered to produce levels of between 40 ng FVIIa/ml and 4 .mu.g FVIIa/ml of plasma. The effective dosages of both tTF and FVIIa are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs.
REFERENCES:
patent: 4479938 (1989-10-01), Thomas
patent: 5180583 (1993-01-01), Hedner
patent: 5298599 (1994-03-01), Rezaie et al.
patent: 5346991 (1994-09-01), Roy et al.
Neuenschwander et al. "Deletion of the Membrane Anchoring Region of Tissue Factor Abolishes Autoactivation of Factor VII but Not Cofactor Function" J Biol. Chem. 267(20):14477-14482, 1992.
Waxman, et al., "Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with Factor VIIa and enzymatic activity of the complex," Biochem 31:3998-4003 (1992).
Guha, et al., "The defect in the coagulant activity of soluble human tissue factor is not the result of impaired Factor VIIa binding," FASEB J 6:A328 (1992).
Bach, et al., "Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine," Biochemistry, 25:4007-4020 (1986).
Brinkhous, et al., "Pathophysiology of platelet-aggregating von Willebrand Factor: applications of the venom coagglutinin vWF assay," An NY Acad Sci 370:191-204 (1981).
Brinkhous, et al., "Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs," Proc Natl Acad Sci USA 82:8752-8756 (1985).
Brinkhous, et al., "Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease," Proc Natl Acad Sci USA 86:1382-1386 (1989).
De Sousa, et al., "Factor VII hyperactivity in acute myocardial thrombosis. a relation to the coagulation activation," Thrombosis Research, 51:165-173 (1988).
Fair, Daryl S., "Quantitation of Factor VII in the plasma of normal and Warfarin-treated individuals by radioimmunoassay," Blood 62:784-791 (1983).
Fisher, et al., "Cloning and expression of human tissue factor cDNA," Thrombosis Research, 48:89-99 (1987).
Giles, et al., "A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo," Br J of Haematology 69:491-497 (1988), England.
Gordon, et al., "Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII, and spontaneous shortening of prothrombin time in survivors of myocardial infarction," J. Lab. Clin. Med., 109:409-413 (1987).
Graham, et al., "Canine hemophilia," J Exp Med, pp. 97-111 (1949).
Hagen, et al., "Characterization of a cDNA coding for human factor VII," Proc Natl Acad Sci USA 83:2412-2416 (1986).
Hapak, et al., "The location of the active site of Factor VIIa above the membrane surface is altered by either full-length or truncated tissue factor," FASEB Journal 6:A330, Abstract No. 1900 (1992).
Hedner, et al., "Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors," J Clin Invest 71:1836-1841 (1983).
Hedner, Ulla, "Experiences with recombinant Factor VIIa in haemophiliacs," Biotechnology of Plasma Proteins Curr Stud Hematol Blood Transf 58:63-68 (1991), Switzerland.
Hoffman, et al., "Factor VII activity state in coronary artery disease," J. Lab. Clin. Med., 111:475-481 (1988).
Kisiel, et al., "Activiation of bovine Factor VII (Proconvertin) by Factor XII.sub.a (activated Hageman factor)," Biochemistry 16:4189-4194 (1977).
Lawson, et al., "The evaluation of complex-dependent alterations in human Factor VIIa," J. Biol. Chem., 267:4834-4843 (1992).
Mackman, et al., "Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade," Biochemistry, 28:1755-1762 (1989).
Masys, et al., "Activation of human Factor VII by activated Factors IX and X," Blood 60:1143-1150 (1982).
Mitropoulos, "Hypercoagulability and Factor VII in hypertriglyceridemia," Seminars in Thrombosis and Hemostasis, 14:246-251 (1988).
Morrissey, et al., "Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade," Cell 50:129-135 (1987).
Morrissey, et al., "Monoclonal antibody analysis of purified and cell-associated tissue factor," Thrombosis Research 52:247-261 (1988).
Morrissey, et al., "Quantitation of activated Factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting Factor VII activation," Blood 81:734-744 (1993).
Nakagaki, et al., "Activation of human Factor VII by the prothrombin activator from the venom of Oxyuranus Scutellatus (Taipan Snake)," Thrombosis Research 65:105-116 (1992).
Nemerson, "Tissue factor and hemostasis," Blood, 71:1-8 (1988).
O'Brien, et al., "Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model," J Clin Invest 82:206-211 (1988).
Paborsky, et al., "Purification of recombinant human tissue factor," Biochemistry, 28:8072-8077 (1989).
Paborsky and Harris, "Post-translational modifications of recombinant human tissue factor," Thrombosis Research, 60:367-376 (1990).
Paborsky, et al., "Lipid association, but not the transmembrane domain, is required for tissue factor activity," J Biol Chem 266:21911-21916 (1991).
Poggio, et al., "Factor VII clotting assay: influence of different thromboplastins and Factor VII-deficient plasmas," Thrombosis Haemostasis, 65:160-164 (1991).
Radcliffe, et al., "Activation and control of Factor VII by activated Factor X and thrombin," J Biol Chem 250:388-395 (1975).
Rehemtulla, et al., "The isolated extracellular domain of tissue factor is functional on phospholipid surfaces," Thrombosis Haemostasis 62:347 (1989), Germany.
Rezaie, et al., "Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody," Protein Expression and Purification 3:453-460 (1992).
Ruf, et al., "The isolated extracellular domain of tissue factor is functional on phopholipid surfaces," Thrombosis & Haemostasis 62:347 (1989).
Ruf, et al., "Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function," J Biol Chem 266:2158-2166 (1991).
Sakai, et al., "Formation of tissue factor activity following incubation of recombinant human tissue factor apoprotein with plasma lipoproteins," Thrombosis Research 60:213-222 (1990).
Scarabin, et al., "Is Factor VII activation in pregnant women relevant to fetal growth retardation?," Thrombosis Research, 45:845-850 (1987).
Scarpati, et al., "Human tissue factor: cDNA sequence and chromosome localization of the gene," Biochemistry, 26:5234-5238 (1987).
Seligsohn, et al., "Coupled amidolytic assay for Factor VII: its use with a clotting assay to determine the activity state of Factor VII," Blood 52:978-988 (1978).
Shigematsu, et al., "Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with Factor VIIa," J Biol Chem 267:21329-21337 (1992).
Spicer, et al., "Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA," Proc. Natl. Acad. Sci. USA, 84:5148-5152 (1987).
Teitel, Jerome M., "The Factor VIII bypassing activity of prothrombin complex concentrates: the roles of VIIa and of endothelial cell tissue factor," Thrombosis Haemostasis 66:559-564 (1991).
Telgt, et al., "Mechanism by which recombinant Factor VIIa shortens the aPTT: activation of Factor X in the absence of tissue factor," Thrombosis Research 56:603-609 (1989).
Zur, et al., "The dual role of Factor VII in blood coagulation," J. Biol. Chem., 257:5623-5631 (1982).
Comp Philip C.
Morrissey James H.
Degen Nancy J.
Oklahoma Medical Research Foundation
Wityshyn Michael G.
LandOfFree
Treatment of bleeding with modified tissue factor in combination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of bleeding with modified tissue factor in combination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of bleeding with modified tissue factor in combination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2016360